|
1
|
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu
W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Normanno N, De Luca A, Bianco C, Strizzi
L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and
Salomon DS: Epidermal growth factor receptor (EGFR) signaling in
cancer. Gene. 366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Honeth G, Bendahl PO, Ringnér M, Saal LH,
Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and
Hegardt C: The CD44+/CD24− phenotype is
enriched in basal-like breast tumors. Breast Cancer Res.
10:R532008.
|
|
5
|
Kim S, Han J, Kim JS, Kim JH, Choe JH,
Yang JH, Nam SJ and Lee JE: Silibinin suppresses EGFR
ligand-induced CD44 expression through inhibition of EGFR activity
in breast cancer cells. Anticancer Res. 31:3767–3773.
2011.PubMed/NCBI
|
|
6
|
Gotte M and Yip GW: Heparanase,
hyaluronan, and CD44 in cancers: a breast carcinoma perspective.
Cancer Res. 66:10233–10237. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naor D, Sionov RV and Ish-Shalom D: CD44:
structure, function, and association with the malignant process.
Adv Cancer Res. 71:241–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karihtala P, Soini Y, Auvinen P, Tammi R,
Tammi M and Kosma VM: Hyaluronan in breast cancer: correlations
with nitric oxide synthases and tyrosine nitrosylation. J Histochem
Cytochem. 55:1191–1198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naor D, Nedvetzki S, Golan I, Melnik L and
Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579.
2002. View Article : Google Scholar
|
|
10
|
Turley EA, Noble PW and Bourguignon LY:
Signaling properties of hyaluronan receptors. J Biol Chem.
277:4589–4592. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bourguignon LY: CD44-mediated oncogenic
signaling and cytoskeleton activation during mammary tumor
progression. J Mammary Gland Biol Neoplasia. 6:287–297. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tölg C, Hofmann M, Herrlich P and Ponta H:
Splicing choice from ten variant exons establishes CD44
variability. Nucleic Acids Res. 21:1225–1229. 1993.PubMed/NCBI
|
|
13
|
Ouhtit A, Abd Elmageed ZY, Abdraboh ME,
Lioe TF and Raj MH: In vivo evidence for the role of CD44s in
promoting breast cancer metastasis to the liver. Am J Pathol.
171:2033–2039. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bourguignon LY, Gunja-Smith Z, Iida N, Zhu
HB, Young LJ, Muller WJ and Cardiff RD: CD44v3,8–10 is
involved in cytoskeleton-mediated tumor cell migration and matrix
metal-loproteinase (MMP-9) association in metastatic breast cancer
cells. J Cell Physiol. 176:206–215. 1998.
|
|
15
|
Takada Y, Murakami A and Aggarwal BB:
Zerumbone abolishes NF-κB and IκBα kinase activation leading to
suppression of antiapoptotic and metastatic gene expression,
upregulation of apoptosis, and downregulation of invasion.
Oncogene. 24:6957–6969. 2005.
|
|
16
|
Murakami A and Ohigashi H:
Cancer-preventive anti-oxidants that attenuate free radical
generation by inflammatory cells. Biol Chem. 387:387–392. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Murakami A, Takahashi D, Kinoshita T,
Koshimizu K, Kim HW, Yoshihiro A, Nakamura Y, Jiwajinda S, Terao J
and Ohigashi H: Zerumbone, a Southeast Asian ginger sesquiterpene,
markedly suppresses free radical generation, proinflammatory
protein production, and cancer cell proliferation accompanied by
apoptosis: the α,β-unsaturated carbonyl group is a prerequisite.
Carcinogenesis. 23:795–802. 2002.PubMed/NCBI
|
|
18
|
Sung B, Jhurani S, Ahn KS, Mastuo Y, Yi T,
Guha S, Liu M and Aggarwal BB: Zerumbone down-regulates chemokine
receptor CXCR4 expression leading to inhibition of CXCL12-induced
invasion of breast and pancreatic tumor cells. Cancer Res.
68:8938–8944. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Normanno N, Bianco C, Strizzi L, Mancino
M, Maiello MR, De Luca A, Caponigro F and Salomon DS: The ErbB
receptors and their ligands in cancer: an overview. Curr Drug
Targets. 6:243–257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Normanno N, Bianco C, De Luca A, Maiello
MR and Salomon DS: Target-based agents against ErbB receptors and
their ligands: a novel approach to cancer treatment. Endocr Relat
Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lurje G and Lenz HJ: EGFR signaling and
drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eccles SA: The epidermal growth factor
receptor/Erb-B/HER family in normal and malignant breast biology.
Int J Dev Biol. 55:685–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schulze WX, Deng L and Mann M:
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol
Syst Biol. 1:2005.0008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang M, Singh RK, Wang MH, Wells A and
Siegal GP: Epidermal growth factor modulates cell attachment to
hyal-uronic acid by the cell surface glycoprotein CD44. Clin Exp
Metastasis. 14:268–276. 1996.PubMed/NCBI
|
|
25
|
Zhang M, Wang MH, Singh RK, Wells A and
Siegal GP: Epidermal growth factor induces CD44 gene expression
through a novel regulatory element in mouse fibroblasts. J Biol
Chem. 272:14139–14146. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martin TA, Harrison G, Mansel RE and Jiang
WG: The role of the CD44/ezrin complex in cancer metastasis. Crit
Rev Oncol Hematol. 46:165–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamb RF, Hennigan RF, Turnbull K,
Katsanakis KD, MacKenzie ED, Birnie GD and Ozanne BW: AP-1-mediated
invasion requires increased expression of the hyaluronan receptor
CD44. Mol Cell Biol. 17:963–976. 1997.PubMed/NCBI
|
|
28
|
Xian M, Ito K, Nakazato T, Shimizu T, Chen
CK, Yamato K, Murakami A, Ohigashi H, Ikeda Y and Kizaki M:
Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle
arrest and apoptosis in leukemia cells via a Fas- and
mitochondria-mediated pathway. Cancer Sci. 98:118–126. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shamoto T, Matsuo Y, Shibata T, Tsuboi K,
Nagasaki T, Takahashi H, Funahashi H, Okada Y and Takeyama H:
Zerumbone inhibits angiogenesis by blocking NF-κB activity in
pancreatic cancer. Pancreas. 43:396–404. 2014.PubMed/NCBI
|
|
30
|
Ali HR, Dawson SJ, Blows FM, Provenzano E,
Pharoah PD and Caldas C: Cancer stem cell markers in breast cancer:
pathological, clinical and prognostic significance. Breast Cancer
Res. 13:R1182011. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA,
Parmiani G, Castelli C and Clarke MF: Phenotypic characterization
of human colorectal cancer stem cells. Proc Natl Acad Sci USA.
104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Herishanu Y, Gibellini F, Njuguna N,
Hazan-Halevy I, Farooqui M, Bern S, Keyvanfar K, Lee E, Wilson W
and Wiestner A: Activation of CD44, a receptor for extracellular
matrix components, protects chronic lymphocytic leukemia cells from
spontaneous and drug induced apoptosis through MCL-1. Leuk
Lymphoma. 52:1758–1769. 2011. View Article : Google Scholar
|
